Therapeutic plasmapheresis for post-operative hepatic failure
Tani, T.; Endo, Y.; Yoshioka, T.; Aoki, H.; Matsuda, K.; Numa, K.; Hanasawa, K.; Kodama, M.
Progress in Clinical and Biological Research 337: 213-220
1990
ISSN/ISBN: 0361-7742 PMID: 2352979 Document Number: 359117
It goes without saying that post-surgical hepatic failure must be treated. But today, the prognosis is very poor. The reasons for this are that HF is usually accompanied by hemostatic disorders and PHF, and the patients have fresh wounds and are under surgical stress. Moreover, there is no treatment, except PE, and this requires an anticoagulant. Nafamostat Mesilate (FUT-175) was invented as a serine protease inhibitor. It is short acting, and its degradation does not require the liver. FUT-175 was applied as an anticoagulant to 15 PHF patients with bleeding. There were no side effects and no aggravation of bleeding. Based on these results, FUT-175 is thought to be an ideal anticoagulant.